Necitumumab

(Portrazza®)

Portrazza®

Drug updated on 11/10/2023

Dosage FormInjection (intravenous; 800 mg/50 mL)
Drug ClassMonoclonal antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.